How anticipated COVID-19 vaccines are bulk manufactured under Operation Warp Speed

With $628 million from the U.S. government, Emergent Bio-Solutions in Baltimore is scaling up separate Johnson & Johnson and AstraZeneca COVID-19 vaccines, which are still pending FDA approval.